BARR SALES DROP 42% FOR YEAR AFTER FDA RULING; ZENECA CASE YIELDS $7.9 MIL. PROFIT
Executive Summary
Barr Labs sales for the year ended June 30 plunged 42% as a result of the suspension of much of the generic drug manufacturer's product line following litigation with FDA. Barr reported sales of $58 mil. for the year, compared to $100.8 mil. for fiscal 1992. On Feb. 4, Newark federal court Judge Alfred Wolin ordered Barr to cease distribution of 24 products following a court case between Barr and FDA over manufacturing compliance issues. Despite the regulatory setback, Barr posted a $7.9 mil. profit for the year on the strength of $21 mil. in payments from Zeneca as part of a settlement of patent litigation relating to Nolvadex. Without the payments, Barr said, it would have lost $5 mil. for the year. Barr lost $1.9 mil. in fiscal 1992. Barr will begin marketing a generic tamoxifen supplied by Zeneca Nov. 1 as part of the March settlement. The firm has reintroduced eight of the suspended products and "is optimistic that it will continue to reintroduce other suspended products." Genetics Institute posted product sales of $25.9 mil. for the nine months ended Aug. 31, the company reported. Third quarter product sales were $9.1 mil. The figures represent sales of Factor VIII concentrate to Baxter.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth